Karyopharm Therapeutics Inc. Revenue 2011–2025
Karyopharm Therapeutics Inc. annual/quarterly revenue history and growth rate from 2011 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Karyopharm Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 35.1 M, a 16.83% increase year-over-year.
- Karyopharm Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 147.1 M, a 2.42% decrease year-over-year.
- Karyopharm Therapeutics Inc. annual revenue for 2025 was 146.1 M, a 0.57% increase from 2024.
- Karyopharm Therapeutics Inc. annual revenue for 2024 was 145.2 M, a 0.55% decrease from 2023.
- Karyopharm Therapeutics Inc. annual revenue for 2023 was 146.0 M, a 7.03% decrease from 2022.
- Karyopharm Therapeutics Inc. annual revenue for 2022 was 157.1 M.
Karyopharm Therapeutics Inc. (KPTI) — Frequently Asked Questions
Karyopharm Therapeutics Inc. (KPTI) is a publicly traded US company. It has a market capitalization of $99,727.2. In fiscal 2025 it reported revenue of $146M and net income of -$196M. Explore KPTI's stock price, financial statements, earnings history, margins and key ratios below.
What is Karyopharm Therapeutics Inc.'s market cap?
Karyopharm Therapeutics Inc. (KPTI) has a market capitalization of $99,727.2.
What is the KPTI stock price?
KPTI trades at $9.12 (+0.11% on the day).
How much revenue does Karyopharm Therapeutics Inc. make?
Karyopharm Therapeutics Inc. reported revenue of $146M in fiscal 2025.
Is KPTI profitable?
In fiscal 2025, Karyopharm Therapeutics Inc. reported net income of -$196M.